Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - dexmedetomidine hydrochloride, quantity: 236 microgram (equivalent: dexmedetomidine, qty 200 microgram) - injection, concentrated - excipient ingredients: sodium chloride; water for injections - intensive care unit (icu) sedation,for sedation of initially intubated patients during treatment in an intensive care setting. the use of dexmedetomidine kabi by continuous infusion in these patients should not exceed 24 hours.,procedural sedation,for sedation of non-intubated patients prior to and/or during surgical and other procedures.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - dexmedetomidine hydrochloride, quantity: 1180 microgram (equivalent: dexmedetomidine, qty 1000 microgram) - injection, concentrated - excipient ingredients: sodium chloride; water for injections - intensive care unit (icu) sedation,for sedation of initially intubated patients during treatment in an intensive care setting. the use of dexmedetomidine kabi by continuous infusion in these patients should not exceed 24 hours.,procedural sedation,for sedation of non-intubated patients prior to and/or during surgical and other procedures.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 314 microgram (equivalent: fentanyl, qty 200 microgram) - tablet, orally disintegrating - excipient ingredients: magnesium stearate; sodium bicarbonate; mannitol; citric acid; sodium starch glycollate type a; sodium carbonate - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 157 microgram (equivalent: fentanyl, qty 100 microgram) - tablet, orally disintegrating - excipient ingredients: mannitol; sodium carbonate; sodium bicarbonate; citric acid; sodium starch glycollate type a; magnesium stearate - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 943 microgram (equivalent: fentanyl, qty 600 microgram) - tablet, orally disintegrating - excipient ingredients: sodium bicarbonate; magnesium stearate; sodium carbonate; sodium starch glycollate type a; citric acid; mannitol - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - fentanyl citrate, quantity: 628 microgram (equivalent: fentanyl, qty 400 microgram) - tablet, orally disintegrating - excipient ingredients: magnesium stearate; sodium carbonate; sodium starch glycollate type a; sodium bicarbonate; citric acid; mannitol - fentora is indicated for the treatment of breakthrough pain (btp) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fingolimod hydrochloride, quantity: 560 microgram (equivalent: fingolimod, qty 500 microgram) - capsule - excipient ingredients: calcium hydrogen phosphate dihydrate; glycine; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide yellow; iron oxide red; potable water; gelatin; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - fynod is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram); mometasone furoate, quantity: 320 microgram - capsule, hard - excipient ingredients: lactose monohydrate - atectura breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:,- patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or,- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram); mometasone furoate, quantity: 160 microgram; glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram); mometasone furoate, quantity: 80 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.